This $398,415 Project Grant was awarded on August 5, 2024 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The purpose of the award is to support the development of Regenosine, Inc.'s first-in-class liposomal adenosine product RGNA09M for the treatment and prevention of osteoarthritis. The funding will be used to validate analytical methods, implement CGMP manufacturing processes, and produce a 1-liter sterile CGMP batch of RGNA09M for upcoming Phase 1b/2a clinical trials. The goal is to advance this novel, disease-modifying regenerative therapy through the required FDA regulatory steps towards commercialization, with the intent of significantly improving clinical outcomes and reducing healthcare costs associated with osteoarthritis.